Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Endocyte
Biotech
Novartis tags Molecular Partners for $580M radioligand deal
Novartis has partnered with Molecular Partners to develop cancer candidates that target tumors for $20 million upfront plus $560 million in biobucks.
Annalee Armstrong
Dec 14, 2021 10:34am
Novartis links cancer drug to improved pain, quality of life
Sep 16, 2021 6:05pm
Novartis backs up Endocyte buyout with prostate cancer data
Jun 3, 2021 12:40pm
Novartis' radioligand hits goal in phase 3 prostate cancer trial
Mar 23, 2021 7:50am
Novartis inks $2.1B Endocyte buyout
Oct 18, 2018 6:03am
Endocyte licenses ‘billion-dollar’ prostate cancer drug
Oct 2, 2017 9:07am
